Charles Schwab Investment Management Inc Beyond Spring Inc. Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.13 - $2.66 $56,037 - $131,912	-49,591 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$4.02 - $16.84 $8,916 - $37,351	2,218 Added 4.68%	49,591 $225,000
Q3 2021 Nov 16, 2021	SELL	$9.26 - $31.31 $814 - $2,755	-88 Reduced 0.19%	47,373 $747,000
Q2 2021 Aug 16, 2021	BUY	$9.37 - $12.12 $64,793 - $83,809	6,915 Added 17.05%	47,461 $496,000
Q1 2021 May 17, 2021	BUY	$10.61 - $15.77 $107,532 - $159,828	10,135 Added 33.33%	40,546 $449,000
Q3 2020 Nov 13, 2020	BUY	$9.99 - $16.13 $11,988 - $19,356	1,200 Added 4.11%	30,411 $405,000
Q2 2020 Aug 14, 2020	BUY	$11.21 - $18.15 $21,366 - $34,593	1,906 Added 6.98%	29,211 $441,000
Q4 2019 Feb 07, 2020	BUY	$11.83 - $18.68 $25,505 - $40,274	2,156 Added 8.57%	27,305 $424,000
Q3 2019 Nov 08, 2019	BUY	$15.33 - $23.85 $44,273 - $68,878	2,888 Added 12.97%	25,149 $456,000
Q2 2019 Aug 09, 2019	BUY	$13.36 - $23.7 $297,406 - $527,585	22,261 New	22,261 $528,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $66.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.